RxSight, Inc. (RXST)
NASDAQ: RXST · Real-Time Price · USD
13.75
+0.69 (5.28%)
At close: May 12, 2025, 4:00 PM
14.00
+0.25 (1.82%)
After-hours: May 12, 2025, 5:53 PM EDT
RxSight Revenue
RxSight had revenue of $37.90M in the quarter ending March 31, 2025, with 28.41% growth. This brings the company's revenue in the last twelve months to $148.31M, up 46.70% year-over-year. In the year 2024, RxSight had annual revenue of $139.93M with 57.09% growth.
Revenue (ttm)
$148.31M
Revenue Growth
+46.70%
P/S Ratio
3.69
Revenue / Employee
$297,811
Employees
498
Market Cap
558.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 139.93M | 50.85M | 57.09% |
Dec 31, 2023 | 89.08M | 40.07M | 81.77% |
Dec 31, 2022 | 49.01M | 26.41M | 116.90% |
Dec 31, 2021 | 22.59M | 7.92M | 53.92% |
Dec 31, 2020 | 14.68M | 12.44M | 554.98% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2006 | Pro | Pro | Pro |
Dec 31, 2005 | Pro | Pro | Pro |
Dec 31, 2004 | Pro | Pro | Pro |
Dec 31, 2003 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RXST News
- 3 days ago - Top 3 Health Care Stocks That Are Preparing To Pump This Quarter - Benzinga
- 5 days ago - RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - RxSight, Inc. to Present at the Bank of America Healthcare Conference - GlobeNewsWire
- 5 weeks ago - RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) - Seeking Alpha
- 5 weeks ago - RxSight, Inc. (RXST) Q1 2025 Preliminary Results Conference Call (Transcript) - Seeking Alpha
- 5 weeks ago - RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance - GlobeNewsWire
- 6 weeks ago - RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - RxSight, Inc. (RXST) Q4 2024 Earnings Call Transcript - Seeking Alpha